Stroke News and Research

RSS

A stroke is a medical emergency. Strokes happen when blood flow to your brain stops. Within minutes, brain cells begin to die. There are two kinds of stroke. The more common kind, called ischemic stroke, is caused by a blood clot that blocks or plugs a blood vessel in the brain. The other kind, called hemorrhagic stroke, is caused by a blood vessel that breaks and bleeds into the brain. "Mini-strokes" or transient ischemic attacks (TIAs), occur when the blood supply to the brain is briefly interrupted.

SBRT stops the growth of cancer for 98% of patients with NSCLC

Stereotactic body radiation therapy (SBRT) stopped the growth of cancer at its original site in the lung for three years among nearly 98 percent of patients with early non-small cell lung cancer (NSCLC) who are unable to have the cancer surgically removed, according to an updated three-year study presented November 2, 2009, at the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO).

3 Nov 2009

Seaside Therapeutics commences STX107 Phase 1 clinical trial for Fragile X Syndrome

Seaside Therapeutics LLC today announced that the Company has initiated a Phase 1 clinical trial of STX107, a highly potent, selective mGluR5 antagonist, in development for the treatment of Fragile X Syndrome. The single ascending dose study is designed to evaluate the safety, tolerability and pharmacokinetics of STX107 in healthy volunteers. Fragile X Syndrome is the most common inherited form of mental impairment and the most common known cause of autism.

3 Nov 2009

Sexual relationships were significantly affected after a stroke, says study

Dr Assumpta Ryan and Hilary Thompson recently published findings from a study involving 16 married stroke survivors - nine males and seven females - aged between 33 and 78.

3 Nov 2009

Lifestyle changes prevents type 2 diabetes in people at high risk for developing the disease: Study

Sustaining modest weight loss for 10 years, or taking an anti-diabetic drug over that time, can prevent or lower the incidence of type 2 diabetes in people at high risk for developing the disease, according to the Diabetes Prevention Program Outcomes Study (DPPOS), a long-term follow-up to a landmark 2001 diabetes prevention study.

3 Nov 2009

Phase 1 study of STX107 for Fragile X syndrome begins

NIH-supported scientists at Seaside Therapeutics in Cambridge, Mass., are beginning a clinical trial of a potential medication designed to correct a central neurochemical defect underlying Fragile X syndrome, the most common inherited cause of intellectual disability. There has to date been no medication that could alter the disorder's neurologic abnormalities. The study will evaluate safety, tolerability, and optimal dosage in healthy volunteers.

3 Nov 2009

NIA funds national Testosterone Trial, Penn Medicine to lead

Penn Medicine will lead a new national $45 million clinical trial to test whether testosterone therapy can favorably affect certain conditions affecting older men. Low serum testosterone may contribute to a number of problems affecting older men, including decreased ability to walk, loss of muscle mass and strength, decreased vitality, decreased sexual function, impaired cognition, cardiovascular disease and anemia. While testosterone normally decreases with age, in some men, low levels of testosterone may contribute to these debilitating conditions.

2 Nov 2009

Aetna inks three-year agreement with HHC

Aetna announced today that it has reached an agreement with the New York City Health and Hospitals Corporation (HHC) to offer Aetna members in New York City in-network access to in-patient and out-patient services from HHC’s 11 acute care hospitals, six Diagnostic and Treatment Centers and four nursing homes.

2 Nov 2009

NIH awards $2 million grant for sickle cell disease research

Researchers at the University of Illinois at Chicago will use a $2 million federal grant to investigate why patients with sickle cell disease experience chronic pain -- and to develop drugs to treat it.

2 Nov 2009

St. David's Medical Center to use FDA cleared CARTO 3 Navigation System for treating cardiac arrhythmia

On Monday, November 2, 2009, Andrea Natale, M.D., F.A.C.C., F.H.R.S., an electrophysiologist and executive medical director of the Texas Cardiac Arrhythmia Institute at St. David's Medical Center, will be the first physician in the United States to perform an ablation procedure to treat a patient with a cardiac arrhythmia, commonly known as an irregular heart rhythm, using the newly FDA-cleared CARTO® 3 Navigation System.

2 Nov 2009

MTD Products and AHA team up to promote heart health and winter safety

What do sipping cocoa, snuggling under blankets and heart attacks all have in common? They are all more common during the cold winter months.

2 Nov 2009

Dietary cholesterol is not a primary factor for coronary heart disease

Contrary to the established view, current data suggest that dietary cholesterol is not a primary factor of or causes heart disease - with the possible exception of the genetic forms of familial hypercholesterolemias. For instance, recent clinical trials evaluating the effect of cholesterol-lowering drugs on the development of chronic heart failure, diabetes and stroke have yielded disappointing results.

2 Nov 2009

American Diabetes Association launches "Stop Diabetes" campaign

Americans earn a failing grade on diabetes awareness, based on survey results released today by the American Diabetes Association. In general, Americans earned a 51% when asked a series of questions about a disease so common that it strikes every 20 seconds. The survey results revealed that many diabetes myths and misconceptions still exist, while the disease's prevalence continues to rise.

2 Nov 2009

Amylin and Takeda to develop and commercialize pharmaceutical products for obesity

Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Takeda Pharmaceutical Company Limited (TSE: 4502) announced today that they have entered into a worldwide exclusive license, development and commercialization agreement to co-develop and commercialize pharmaceutical products for the treatment of obesity and related indications.

2 Nov 2009

CNS cancer survivors have greater neurocognitive dysfunction than survivors of other types of cancer

Brain tumors in childhood cast a long shadow on survivors. The first study of the lasting impact of these tumors -- the most common solid malignancies in childhood -- shows that survivors have ongoing cognitive problems.

2 Nov 2009

Amgen publishes Phase 3 study results of Aranesp

Amgen today announced the publication of results from TREAT (the Trial to Reduce Cardiovascular Events with Aranesp® Therapy), a large, randomized, double-blind, placebo-controlled, Phase 3 pivotal study of patients with chronic kidney disease (CKD) not on dialysis, moderate anemia and type-2 diabetes.

31 Oct 2009

Shire announces Phase IIIb study results of Daytrana

Shire plc, the global specialty biopharmaceutical company, today announced findings at a major medical meeting from a Phase IIIb study of the tolerability and effectiveness of Daytrana® (methylphenidate transdermal system) in adolescents aged 13 to 17 years diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD).

31 Oct 2009

Conference to address the need for gender specific diagnostic strategies for women

The 'Red Alert for Women's Hearts' conference, taking place on 5 November 2009, at the European Heart House, Sophia Antipolis, France, will address the subject of Women and CVD. The conference is jointly organised by the European Society of Cardiology (ESC) and European Heart Network (EHN), as part of Work Package 6 of the EuroHeart project .

31 Oct 2009

WakeMed Health & Hospitals and SCA team up to explore partnership opportunities

WakeMed Health & Hospitals and Surgical Care Affiliates (SCA) have entered into a Letter of Understanding (LOU) under which the two organizations will explore partnership opportunities.

31 Oct 2009

Study: Gene therapy can reduce symptoms of Huntington's disease

Researchers at the California Institute of Technology (Caltech) have shown that a highly specific intrabody (an antibody fragment that works against a target inside a cell) is capable of stalling the development of Huntington's disease in a variety of mouse models.

31 Oct 2009

Geron plans to advance clinical program for spinal cord injury

Geron Corporation today announced the company’s plan to advance clinical development of its human embryonic stem cell (hESC)-based product, GRNOPC1, for the treatment of spinal cord injury.

31 Oct 2009